Skip to results
Modify your search
NARROW
1-20 of 21
Authors: Michael D Ezekowitz
Journal Article
Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF Registry Open Access
European Heart Journal, Volume 45, Issue 26, 7 July 2024, Pages 2336–2340, https://doi.org/10.1093/eurheartj/ehae319
Published: 04 June 2024
Journal Article
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation Open Access
Cardiovascular Research, Volume 118, Issue 9, June 2022, Pages 2112–2123, https://doi.org/10.1093/cvr/cvab262
Published: 06 August 2021
Journal Article
Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial Free
in
EP Europace
EP Europace, Volume 23, Issue 10, October 2021, Pages 1539–1547, https://doi.org/10.1093/europace/euab084
Published: 13 June 2021
Journal Article
Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease Free
Cardiovascular Research, Volume 118, Issue 1, January 2022, Pages 295–304, https://doi.org/10.1093/cvr/cvaa344
Published: 02 January 2021
Journal Article
EDITOR'S CHOICE
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation Free
European Heart Journal, Volume 41, Issue 41, 1 November 2020, Pages 4037–4046, https://doi.org/10.1093/eurheartj/ehaa697
Published: 27 September 2020
Journal Article
Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions Free
European Heart Journal - Quality of Care and Clinical Outcomes, Volume 6, Issue 4, October 2020, Pages 263–272, https://doi.org/10.1093/ehjqcco/qcaa040
Published: 11 May 2020
Journal Article
Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis Free
in
EP Europace
EP Europace, Volume 22, Issue 6, June 2020, Pages 870–877, https://doi.org/10.1093/europace/euz360
Published: 26 March 2020
Journal Article
Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis Open Access
in
EP Europace
EP Europace, Volume 21, Issue 11, November 2019, Pages 1633–1638, https://doi.org/10.1093/europace/euz213
Published: 22 August 2019
Journal Article
Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study Open Access
in
EP Europace
EP Europace, Volume 20, Issue 12, December 2018, Pages 1936–1943, https://doi.org/10.1093/europace/euy141
Published: 27 June 2018
Journal Article
EDITOR'S CHOICE
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial Open Access
European Heart Journal, Volume 39, Issue 32, 21 August 2018, Pages 2959–2971, https://doi.org/10.1093/eurheartj/ehy148
Published: 06 April 2018
Journal Article
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score Open Access
European Heart Journal, Volume 39, Issue 6, 07 February 2018, Pages 477–485, https://doi.org/10.1093/eurheartj/ehx584
Published: 21 October 2017
Journal Article
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study Open Access
in
EP Europace
EP Europace, Volume 20, Issue 2, February 2018, Pages 253–262, https://doi.org/10.1093/europace/eux022
Published: 17 May 2017
Journal Article
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation Free
in
EP Europace
EP Europace, Volume 18, Issue 7, July 2016, Pages 973–978, https://doi.org/10.1093/europace/euv312
Published: 03 March 2016
Journal Article
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1 Free
European Heart Journal, Volume 38, Issue 12, 21 March 2017, Pages 852–859, https://doi.org/10.1093/eurheartj/ehv643
Published: 04 February 2016
Journal Article
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2 Free
European Heart Journal, Volume 38, Issue 12, 21 March 2017, Pages 860–868, https://doi.org/10.1093/eurheartj/ehw069
Published: 04 February 2016
Journal Article
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial Open Access
in
EP Europace
EP Europace, Volume 18, Issue 2, February 2016, Pages 184–190, https://doi.org/10.1093/europace/euv294
Published: 20 October 2015
Journal Article
EDITOR'S CHOICE
FAST TRACK
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation Get access
European Heart Journal, Volume 35, Issue 47, 14 December 2014, Pages 3346–3355, https://doi.org/10.1093/eurheartj/ehu367
Published: 02 September 2014
Journal Article
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa) Open Access
European Heart Journal, Volume 34, Issue 20, 21 May 2013, Pages 1498–1505, https://doi.org/10.1093/eurheartj/eht039
Published: 13 March 2013
Journal Article
2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society
Free
in
EP Europace
EP Europace, Volume 14, Issue 4, April 2012, Pages 528–606, https://doi.org/10.1093/europace/eus027
Published: 01 March 2012
Journal Article
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial Get access
European Heart Journal, Volume 26, Issue 9, May 2005, Pages 890–896, https://doi.org/10.1093/eurheartj/ehi186
Published: 11 March 2005
